PATENT CLAIM ANALYSIS

Application Number: 16415552
Application Type: Utility
Filing Date: 2019-05
Publication Date: 2019-10
Patent Classification: ["424", "134100"]

Abstract:
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Claim (Index 1):
A method of eliciting an immune response in a HLA-A*02+ patient who has cancer, comprising administering to the patient a population of activated antigen-specific CD8+ cytotoxic T cells that kill cancer cells that present at their surface a peptide consisting of the amino acid sequence selected from SEQ ID NO: 120, SEQ ID NO: 203, SEQ ID NO: 2 to SEQ ID NO: 112, SEQ ID NO: 114 to SEQ ID NO: 119, SEQ ID NO: 121 to SEQ ID NO: 145, SEQ ID NO: 147 to SEQ ID NO: 202, SEQ ID NO: 204 to SEQ ID NO: 273, and SEQ ID NO: 275 to SEQ ID NO: 328, in a complex with an MHC class I molecule,\n wherein the activated antigen-specific CD8+ cytotoxic cells are produced by a method comprising contacting in vitro CD8+ cytotoxic T cells with an antigen presenting cell presenting at its surface a peptide consisting of the amino acid sequence selected from SEQ ID NO: 120, SEQ ID NO: 203, SEQ ID NO: 2 to SEQ ID NO: 112, SEQ ID NO: 114 to SEQ ID NO: 119, SEQ ID NO: 121 to SEQ ID NO: 145, SEQ ID NO: 147 to SEQ ID NO: 202, SEQ ID NO: 204 to SEQ ID NO: 273, and SEQ ID NO: 275 to SEQ ID NO: 328 in a complex with an MHC class I molecule, wherein said cancer is selected from the group consisting of non-Hodgkin lymphomas, acute myelogenous leukemia, chronic lymphocytic leukemia, uterine cancer, lung cancer, kidney cancer, brain cancer, stomach cancer, colon or rectal cancer, liver cancer, prostate cancer, leukemia, breast cancer, Merkel cell carcinoma (MCC), melanoma, ovarian cancer, esophageal cancer, urinary bladder cancer, endometrial cancer, gall bladder cancer, and bile duct cancer.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 100.0
- Lexical Diversity: 1.61972
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['16192391', '15436385', '16193334', '16192422', '16154457']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8515197521918082
- 35 USC 102 Novelty (BERT): 0.6398651691885567
- Combined Prediction Score: 0.8303542938914831
- Mean Citation Score: 677.395828
- Max Citation Score: 692.7325400000003
- Similarity Product: 553.3000377863707

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test